|
|
|
|
Nivolumab has emerged as an effective treatment for advanced cancers such as melanoma and non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) are sometimes associated with the administration of immune checkpoint inhibitors. Colitis, endocrine dysfunction and myasthenia gravis (MG) are well-known irAEs irAEs induced by nivolumab. Here, we report a case of nivolumab-induced acute demyelinating polyneuropathy. |
|